News Hub | News Direct

The Beachbody Company (NYSE: BODI) Reports Achieving Positive Turnaround In Revenue, EBITDA And Cash Flow In Q1 2024

Benzinga

By James Blacker, Benzinga Subscription health and fitness firm The Beachbody Company, Inc (NYSE: BODI) saw a significant turnaround in its financial results for the first quarter ending March 31, reporting higher revenue and adjusted EBITDA compared to the previous quarter as well as the first positive free cash flow quarter since 2020. Positive Financial Metrics The company, which now goes by BODi, reported a total revenue of $120 million for the first quarter, exceeding the midpoint of guidance. While revenue was down around 17% from $144.9 million in the same period of 2023, the figure grew from $119 million in the previous quarter – representing the first quarter-on-quarter revenue growth since 2021. BODi’s increase in revenue compared to the previous quarter was driven by a more than 7% increase in revenue from its Nutrition & Other segment, while the Digital and Connected Fitness segments saw slight dips in revenue over the same period. A key highlight for the quarter was the company’s first positive free cash flow since 2020, which was $7.4 million, compared to negative $11.3 million in the first quarter of 2023. BODi said it generated $9.1 million from operating activities in Q1 2024, in stark contrast to a cash outflow of $7.9 million from operating activities in the same period of 2023. The company also saw an inflow of $3.9 million from investing activities, compared to an outflow of $3.4 million last year. "Our net cash position increased from $3.9 million at December 31, 2023 to $14.4 million at March 31, 2024, representing approximately a $10 million improvement in our liquidity in one quarter,” noted Marc Suidan, BODi’s Chief Financial Officer. Other key financial metrics also showed positive improvements, with a substantial rise in adjusted EBITDA at $4.6 million, compared to a negative $0.9 million in the first quarter of last year. Moreover, the company narrowed its net loss to $14.2 million in the first quarter from $29.2 million in the year-ago period. BODi’s financial improvement in Q1 2024 was bolstered by a reduction in total operating expenses, which fell to $92.1 million in the first quarter from $118.8 million a year earlier. This helped slash the operating loss by $16.6 million (over 60%!), from $27.4 million to $10.8 million. Outlook For Q2 Looking ahead to the second quarter of 2024 ending June 30, BODi expects to see revenue fall within the range of $103 million to $113 million, with a net loss of between $14 million and $20 million. Adjusted EBITDA in Q2 is projected to be between negative $3 million and positive $3 million. While BODi appears to remain cautious in its Q2 outlook, the positive Q1 results mark a potential turning point for the company. The revenue growth, positive free cash flow and improved adjusted EBITDA signify robust progress in its turnaround plan. Things could be looking up for BODi, provided it can capitalize on the booming online/virtual fitness market, which is projected to grow at a CAGR of 32.7% through 2032, becoming a $250.7 billion market. Key Financial Metrics For The Quarter Ended 31 March Additionally, a comparison of the Market Cap to Last Twelve Months (LTM) Revenue ratio can be found below: Featured photo by StockSnap on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

June 03, 2024 08:45 AM Eastern Daylight Time

Image

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Candel Therapeutics

By Jeremy Golden, Benzinga Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ: CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023. The randomized, controlled clinical trial is specifically looking into the safety and efficacy of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection – if possible – in borderline resectable pancreatic ductal adenocarcinoma (PDAC). Very encouraging results were recently reported by the Needham, Massachusetts-based company. Patients reached an estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in the control group in PDAC. At 24 months, the survival rate was 71.4% in CAN-2409 treated patients compared to only 16.7% in the control group after chemoradiation. Thus, prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable PDAC. Importantly, 4 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with 2 patients surviving more than 50.0 months from enrollment. Only 1 out of 6 patients in the randomized control SoC chemotherapy group remained alive at the data cut-off (50.6 months). No new safety signals were observed, providing further support that multiple injections of CAN-2409 are generally well tolerated. Additionally, there were no dose-limiting toxicities or cases of pancreatitis reported. Previous analysis of resected tumors showed dense aggregates of immune cells – including CD8+, cytotoxic tumor-infiltrating lymphocytes and dendritic cells – in PDAC tissue after CAN-2409 administration. This reinforces the potential of CAN-2409 to activate a robust antitumoral immune response in patients with cancer also in ‘cold’, immunosuppressive tumors like PDAC. “Given the frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective new treatment options are urgently needed,” said Garrett Nichols, MD, MS, Chief Medical Officer of Candel. “We are very encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data in this randomized clinical trial. CAN-2409 was generally well tolerated without significant additional local or systemic toxicity when added to SoC chemoradiation.” Candel’s most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf, replication-defective adenovirus designed to induce an individualized, systemic immune response against the tumor. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. More than 1,000 patients have been dosed with CAN-2409 to date, with a favorable reported tolerability profile and proof of concept in each indication that the company is currently pursuing. CAN-2409 is injected directly into the tumor or target tissue using a localized injection method that is akin to the standard approach for in situ vaccination to elicit an immune response against the injected tumor and uninjected metastases. Long-term survival data in PDAC was recently updated with eight months of further follow-up since the first analysis was presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting. Based on the data presented at SITC, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to Candel Therapeutics for CAN-2409 in combination with valacyclovir for the treatment of patients with PDAC in December 2023. More recently, the FDA also granted Orphan Drug Designation. “The failure of conventional immunotherapy to improve outcomes in pancreatic cancer is attributed to the highly immunosuppressive tumor microenvironment, which is largely devoid of immune cells,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “The immunological changes induced by CAN-2409, evident in the pancreatic tissue and the peripheral blood after administration, suggest that CAN-2409 is able to change the balance between the tumor and the patient’s anti-tumor immune response, which can convert progressive cancer into a chronic disease associated with improved survival.” Featured photo by National Cancer Institute on Unsplash. Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. This article includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, and strategic plans for the Company’s business and product candidates, and other risks identified in the Company’s SEC filings, including the Company’s most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Aljanae Reynolds +1 617-916-5445 areynolds@wheelhouselsa.com Company Website https://www.candeltx.com/

June 03, 2024 08:30 AM Eastern Daylight Time

Image

Introducing the SIGMA 28-45mm F1.8 DG DN | Art, the First Full-Frame F1.8 Zoom Lens for Mirrorless Camera Systems

SIGMA CORPORATION OF AMERICA

SIGMA Corporation of America, the US subsidiary of SIGMA Corporation (CEO: Kazuto Yamaki. Headquarters: Asao-ku, Kawasaki-shi, Kanagawa, Japan) is pleased to announce the SIGMA 28-45mm F1.8 DG DN | Art lens. This is the world's first zoom lens with a constant F1.8 aperture for full-frame mirrorless camera systems. Available for Sony E-mount and L-Mount, this new wide-to-standard zoom spans several popular focal lengths from 28mm to 45mm, with image quality comparable to prime lenses. The SIGMA 28-45mm F1.8 DG DN | Art was developed as a full-frame successor to the SIGMA 18-35mm F1.8 DC HSM | Art (for APS-C DSLR cameras), which in 2013 became the first lens in the world to achieve F1.8 throughout the entire zoom range. While offering the convenience of a zoom, this new lens does not compromise on optical performance. By effectively arranging 3 aspherical lens elements and 5 SLD glass elements, this lens suppresses various aberrations and achieves performance comparable to single focal length lenses, even surpassing the SIGMA 24mm F1.4 DG DN | Art and SIGMA 50mm F1.4 DG DN | Art, which have an established reputation for their optical quality. In particular, the 28-45mm F1.8 DG DN | Art focuses on suppressing axial chromatic aberration, which is often noticeable in large-aperture lenses, to achieve images with minimal coloration on both the focus plane and bokeh, and to demonstrate high optical performance from open aperture. The minimum focusing distance is 30cm (11.8 inches) throughout the entire range, and the maximum magnification ratio of 1:4 is achieved at the 45mm focal length. Featuring internal zoom and HLA (High-response Linear Actuator) autofocus, and an optical design that minimizes focus breathing, the SIGMA 28-45mm F1.8 DG DN | Art is well-suited for video work, including gimbal setups, thanks to its balanced design. The click/de-click switch and lockable aperture ring are designed to suit a variety of personal capture preferences, and the dust- and splash-resistant design also makes it suitable for shooting stills and video out in the elements. The SIGMA 28-45mm F1.8 DG DN | Art lens will be available for $1,349 through authorized retailers in the US in late June 2024. Learn more at the SIGMA America website: https://www.sigmaphoto.com/28-45mm-f1-8-dg-dn-a Exclusively for mirrorless cameras | Compatible with full-frame cameras A | Art SIGMA 28-45mm F1.8 DG DN | Art The world's first* F1.8 full-frame mirrorless zoom. *as of June 2024 by SIGMA The world's first* full-frame, F1.8 maximum aperture zoom lens Excellent optical performance comparable to that of a prime lens High-speed AF and innovative features Supplied accessories: CASE, LENS HOOD LH878-06, FRONT CAP LCF-82 III, REAR CAP LCR Available mounts: L-Mount, Sony E-mount Launch date: June 20, 2024 * Product appearance and specifications are subject to change. * This product is developed, manufactured and sold based on the specifications of E-mount which was disclosed by Sony Corporation under the license agreement with Sony Corporation. * L-Mount is a registered trademark of Leica Camera AG. #SIGMA #SIGMA2845mmF18Art #SIGMAArt #SIGMAArtZoom #SIGMADGDN The SIGMA 28-45mm F1.8 DG DN | Art is the world's first full-frame zoom lens with a constant maximum aperture of F1.8, delivering sharpness and clarity comparable to that of a prime lens. Already the pioneer of unique, large-aperture zoom lenses including the SIGMA 18-35mm F1.8 DC HSM | Art and the SIGMA 24-35mm F2 DG HSM | Art, SIGMA introduces another fast, portable and versatile tool to its Art lineup. In addition to its unprecedented brightness, the SIGMA 28-45mm F1.8 DG DN | Art delivers sharpness and clarity comparable to that of a prime lens throughout its entire zoom range. Also equipped with fast and precise AF and superior operability, this innovative optic turns a new page in the history of zoom lenses and their creative possibilities. It is a lens that will inspire full-frame filmmakers, while bringing unparalleled versatility to stills photographers. * As of June 2024 by SIGMA [Key Features] 1. The world's first* full-frame, F1.8 maximum aperture zoom lens SIGMA has successfully developed the world's first full-frame zoom lens with a maximum aperture of F1.8. The SIGMA 28-45mm F1.8 DG DN | Art incorporates an inner zoom mechanism, a minimum focusing distance of 30cm across the entire zoom range, and a filter size of φ82mm. Despite its advanced feature-set, the lens weighs less than 1kg, making it a portable and versatile option for either hand-held shooting or a gimbal setup. Constant maximum aperture of F1.8 Once a privilege reserved only for prime lenses, the maximum F1.8 aperture allows full-frame camera users to expose hand-held in low light and produce beautiful bokeh, while enjoying the flexibility of a zoom. This unique optical achievement has been created through SIGMA's accumulated optical design experience and advanced production technology at the company's sole production base in Aizu, Japan. Practical and stable inner zoom Employing an inner zoom mechanism, the overall length of the lens remains constant when the focal length or focus distance changes. This means the lens is easy to use when shooting hand-held, highly stable when mounted on a tripod or gimbal, and more resistant to dust and water contamination. Consistent close focus The minimum focusing distance is a constant 30cm across the entire zoom range, with a maximum magnification ratio of 1:4 at the telephoto end, providing excellent close-up shooting capabilities. As well as offering precise focus in confined spaces, the lens can therefore be used close to a subject without affecting sharpness when using the zoom. Premium build at a lighter weight By rights, such a fast zoom should be big and heavy, but while the lens's rigidity and durability protect its sophisticated optical design, this is achieved at a weight of less than 1kg. What's more, this reliable photographic tool uses a versatile filter size of φ82mm, meaning no compromise in portability or convenience. 2. Excellent optical performance comparable to that of a prime lens With each optical aberration meticulously corrected throughout the zoom range, the SIGMA 28-45mm F1.8 DG DN | Art rivals prime lenses for clarity and definition. Thanks to its advanced coatings, the lens produces clear images, even in backlit environments, while focus breathing is thoroughly suppressed, bringing expressive power to filmmakers and photographers. The pinnacle of optical quality in a zoom Through the effective arrangement of 5 SLD elements and 3 aspherical elements, aberrations are rigorously corrected. Axial chromatic aberration, which is particularly noticeable with large-aperture lenses, has been thoroughly suppressed, and the lens delivers clear images with minimal coloration, from sharply focused details to large, smooth bokeh. Suppression of focus breathing When using regular lenses, the angle-of-view can change as focus moves from near to far, affecting precise composition. With the SIGMA 28-45mm F1.8 DG DN | Art this focus breathing is suppressed, enabling natural focus pulls when shooting video. Minimal flare and ghosting Flare and ghosting, which reduce image quality, have been largely eliminated using advanced simulation technology, ensuring the lens renders rich, high-contrast results in all conditions. In addition, in order to keep flare and ghosting to a minimum, the lens uses SIGMA's Nano Porous Coating and Super Multi-Layer Coating, producing superior resistance to backlighting and enabling clear, saturated images in all lighting conditions. 3. High-speed AF speed and innovative features The SIGMA 28-45mm F1.8 DG DN | Art delivers a range of professional features as impressive as its outstanding optical performance. With high-speed and adaptable AF, a durable weather-resistant structure, a de-clickable aperture ring, smooth manual focusing and on-barrel AFL buttons, all features combine to create a versatile photographic tool capable of responding to any situation. Faster focus with a linear motor The lens's AF mechanism uses an HLA (High-response Linear Actuator) to combine accelerated focusing speed with exquisite precision. And because the motor is near-silent it allows video recording without noise. Precise and comfortable manual focusing To deliver delicate and accurate manual focus, the lens employs a bi-wire driven focus ring with optimum torque setting, high resolution and an adjustable rotation angle between 90° and 720°*. This allows filmmakers to pull focus with organic smoothness, and photographers to focus manually with outstanding accuracy. * Only for L-Mount, and with compatible cameras. Aperture ring refinements The lens is equipped with an aperture ring as well as an aperture ring click switch and an aperture ring lock switch, allowing for aperture operation suitable for various shooting situations. Equipped with two AFL buttons Located on the side and on top of the barrel, two customizable* AFL buttons can be easily reached in either horizontal or vertical shooting positions. * Assignment of functions is limited to supported cameras and assignable functions vary depending on the camera. Built to withstand the elements In addition to a dust- and splash-resistant body*, the frontmost surface of the lens is coated with a water- and oil-repellent coating so that it can be used safely even in harsh outdoor environments. * The product is designed to be dust- and splash-resistant but is not waterproof. When using the lens near water, etc., take care not to allow large amounts of water to splash on it. If water gets inside the lens, it may cause a major malfunction and render the lens unrepairable. Includes locking petal-type hood A petal-type hood is included to shield the lens from light. It has a locking mechanism for secure attachment and can be reversed for easier storage. [ Additional Features ] Lens construction: 18 elements in 15 groups (5 SLD, 3 aspherical elements) Inner zoom Inner focus system High-speed AF HLA (High-response Linear Actuator) Compatible with Lens Aberration Correction * Only cameras that are compatible with the function are allowed to use this function. Also, the items that can be corrected may vary depending on the camera, or automatic correction may be performed. * On a camera that allows selecting ON/OFF for lens aberration correction, set the various aberration corrections to ON (AUTO) from the camera menu. Supports DMF and AF+MF Compatible with AF assist (for Sony E-mount only) Nano Porous Coating Super Multi-Layer Coating Water- and Oil-Repellent Coating (front element) Aperture ring Aperture ring click switch Aperture ring lock switch AFL button (2 locations) * Assignment of functions is limited to supported cameras and assignable functions vary depending on the camera. Focus Mode switch Support for switching between linear and non-linear focus ring settings (for L-mount only) * Only cameras that are compatible with the system are allowed to use the system. Dust- and Splash-Resistant Structure * The product is designed to be dust- and splash-resistant but is not waterproof. Take care not to allow large amounts of water to splash on the lens. If water gets inside the lens, it may cause a major malfunction and render the lens unrepairable. Petal-type hood with lock LH878-06 Compatible with SIGMA USB DOCK UD-11 (sold separately / for L-Mount only) Designed to minimize flare and ghosting Every single lens undergoes SIGMA's proprietary MTF measuring system 11-blade rounded diaphragm High-precision, durable brass bayonet mount Mount Conversion Service available "Made in Aizu, Japan" craftsmanship [ Key Specifications ] The following specifications are for L-Mount. Lens Construction: 18 elements in 15 groups (5 SLD, 3 aspherical elements) Angle of view: 75.4 - 51.3° Number of diaphragm blades: 11 (rounded diaphragm) Minimum aperture: F16 Minimum focusing distance: 30cm / 11.9 in. Maximum magnification ratio: 1:4 at 45mm Filter size: 82mm Dimensions (Max. Diam. x Length): 87.8 x 151.4mm / 3.5 x 6.0 in. Weight: 960g / 33.9 oz. [ Product Barcode ] Product Name Barcode L-Mount: 0085126 612696 Sony E-mount: 0085126 612658 [ Accessories: Supplied ] LENS HOOD LH878-06: 0085126 941444 FRONT CAP LCF-82 III: 0085126 930028 REAR CAP LCR II (for L-Mount): 0085126 937256 REAR CAP LCR II (for Sony E-mount): 0085126 929879 [ Accessories: Optional ] SIGMA USB DOCK UD-11 for L-Mount: 0085126 878696 SIGMA WR CERAMIC PROTECTOR 82mm: 0085126 931834 SIGMA WR PROTECTOR 82mm: 0085126 930974 SIGMA PROTECTOR 82mm: 0085126 931100 SIGMA WR UV FILTER 82mm: 0085126 930714 SIGMA WR CIRCULAR PL FILTER 82mm: 0085126 930844 [ Information ] SIGMA Corporation: https://www.sigma-global.com/ SIGMA Global Network: https://www.sigma-global.com/en/corporate/world-network/ Product Information: https://www.sigma-global.com/en/lenses/a024_28_45_18/ [ About SIGMA Corporation ] Craftsmanship. Precision. Dedication. Since 1961, SIGMA has been devoted to the pursuit of advancing photographic technology. Unique to the industry, the family-owned business produces its high-quality, award-winning still photo and cinema camera lenses, DSLR and mirrorless cameras, flashes, filters and accessories from its state-of-the-art manufacturing facility located in Aizu, Japan. In 2012, the company introduced SIGMA Global Vision with three distinct lens lines: Art, Contemporary and Sports. Designed for industry camera mount systems including Canon, Fujifilm, Leica, Nikon, Olympus, Panasonic, Sony and SIGMA, each lens is handcrafted and tested in Japan to ensure a high-performance, premium product that is purpose-built to last. In 2016, the SIGMA Cine lens lineup was launched, further cementing SIGMA as an innovator in imaging engineering. Embodying the core optical DNA that has defined the SIGMA benchmark of excellence, SIGMA Cine lenses meet the needs of advanced 6k and 8k cinema production. Forming the landmark L-Mount alliance alongside Leica and Panasonic in 2018, SIGMA continues its storied tradition of imaging excellence through groundbreaking innovations such as the native L-mount SIGMA fp and fp L full-frame mirrorless digital cameras, announced in July 2019 and March 2021 respectively. These products, along with dozens of award-winning SIGMA Global Vision lenses available in native L-Mount format, demonstrate SIGMA's continued commitment to the creative community through expanded product offerings. With the fp, fp L and these lenses, even more users can now leverage SIGMA's renowned optical formula to achieve their creative vision with ease. For more information about SIGMA America, please visit sigmaphoto.com and SIGMA Blog. Follow SIGMA America (Photo): Facebook | Twitter | Instagram Follow SIGMA Ameica (Cine): Facebook | Twitter | Instagram Contact Details SIGMA Corporation of America Jack Howard +1 631-201-7381 sigma.pr@sigmaphoto.com SDDPR Stacey Doss stacey@sddpr.com Company Website https://www.sigmaphoto.com/

June 03, 2024 08:00 AM Eastern Daylight Time

Image

BestGrowthStocks.com Issues Comprehensive Evaluation of Sirius XM Holdings Inc

Sirius XM Holdings Inc

NEW YORK, NY / News Direct/ June 3rd, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive evaluation of Sirius XM Holdings Inc a leading audio entertainment company in North America with a portfolio of audio businesses including its flagship subscription entertainment service SiriusXM; the ad-supported and premium music streaming services of Pandora; an expansive podcast network; and a suite of business and advertising solutions. Sirius XM Holdings Inc (NASDAQ: SIRI) has recently caught the attention of many investors following a multitude of analyst upgrades while short interest remains relatively high. Best Growth Stock's full report breaks through the noise and offers a comprehensive analysis of Sirius XM’s operations, financials, up to date outstanding shares, chart setup, potential catalysts, recent business combination and much more. Access this full analysis free: https://bestgrowthstocks.com/access-siri-bull-and-bear-case-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) Access this full analysis free: https://bestgrowthstocks.com/access-siri-bull-and-bear-case-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) About Sirius XM Holdings Inc. SiriusXM is the leading audio entertainment company in North America with a portfolio of audio businesses including its flagship subscription entertainment service SiriusXM; the ad-supported and premium music streaming services of Pandora; an expansive podcast network; and a suite of business and advertising solutions. Reaching a combined monthly audience of approximately 150 million listeners, SiriusXM offers a broad range of content for listeners everywhere they tune in with a diverse mix of live, on-demand, and curated programming across music, talk, news, and sports. For more about SiriusXM, please go to: www.siriusxm.com. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Contact Details Best Growth Stocks Steve Macalbry Editor@bestgrowthstocks.com

June 03, 2024 07:46 AM Eastern Daylight Time

Image

News Release

NobleMarriage Launches Advanced Matrimonial App for Muslims Seeking Life Partners

Rev Up Marketers

NobleMarriage, an online matrimonial platform dedicated to helping practicing Muslims find life partners globally, has launched its new Android app. The app features a user-friendly interface while strictly adhering to halal and Shariah values, bolstering a dignified and respectful matchmaking service. With the newly launched app, users can benefit from advanced and personalized search options, robust anti-scam protection, and verified member profiles. Key functionalities include live chat, photo requests, and user shortlisting, catering to a diverse user base and allowing for anonymous connections and controlled profile preferences. NobleMarriage's rigorous review process during registration ensures that only real and verified members can join. This thorough verification includes phone number, email address, and profile picture verification, guaranteeing genuine profiles. The app's advanced algorithms consider preferences such as education level, career choice, location, and social background, enabling instant matches between individuals with similar interests. Female users can keep their photos blurred until they respond to a photo request. Male users also have the option to keep their photos blurred or visible, according to their preferences. Some of the key features of the NobleMarriage App are as follows: Data Protection System: The app employs advanced anti-fraud and data protection systems to create a secure environment, giving users confidence in their search for a life partner. Verification of Every Profile: A dedicated moderation team meticulously verifies every profile on the app, ensuring that only genuine marriage seekers are present. Halal Features: Noble Marriage offers features aligned with Islamic values, including personalized inboxes, blurred images, photo requests, and search filters, preserving privacy and faith adherence. Global User Base: NobleMarriage caters to an international Muslim community and facilitates global connections. Focus on Marriage: The app is dedicated solely to helping Muslims find life partners, discouraging dating-type behavior, and upholding the values of marriage. Getting Started with Noble Marriage is easy. Users must create an account, verify their profile, select and connect with suitable matches, and start the conversation to find their soulmate. For more information and to download the app, visit their website. About NobleMarriage: NobleMarriage is a professional Muslim matchmaker platform designed to help practicing Muslims find life partners in a manner that adheres to Islamic values. The newly launched app makes Noble Marriage's services more accessible and efficient for users. With a focus on safety, authenticity, and halal features, NobleMarriage serves a global community, providing a respectful environment for finding a soulmate. Contact Details NobleMarriage Shaher Al Rahman +44 7501 247364 info@noblemarriage.com Company Website https://noblemarriage.com/

June 03, 2024 07:37 AM Eastern Daylight Time

BestGrowthStocks.com Issues Comprehensive Evaluation of GameStop Corporation

Game Stop Corp

Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive evaluation of GameStop Corp. a Fortune 500 and S&P 500 company that operates as a global, multichannel video game, consumer electronics, and collectibles retailer. GameStop Corp. (NYSE: GME) has recently caught the attention of many investors following the meme-stock rally revitalization and other subsequent events covered in this report. Best Growth Stock's full report breaks through the noise and offers a comprehensive analysis of GameStop’s operations, financials, up to date outstanding shares, recent capital raise, chart setup, possible catalysts, management and much more. Access this full analysis free: https://bestgrowthstocks.com/access-gme-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) Access this full analysis free: https://bestgrowthstocks.com/access-gme-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) About GameStop GameStop Corporation (NYSE: GME) is a Fortune 500 and S&P 500 company that operates as a global, multichannel video game, consumer electronics, and collectibles retailer. The company was founded in 1996 and is headquartered in Grapevine, Texas. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Media Contact Best Growth Stocks Senior Editor: Steve Macalbry Editor@BestGrowthStocks.com SOURCE: BestGrowthStocks.Com Contact Details Best Growth Stocks Steve Macalbry Editor@bestgrowthstocks.com

June 03, 2024 07:30 AM Eastern Daylight Time

Image

News Release

Sector Spotlight: Orphan Drug Developers With Significant Upside

RazorPitch CRDL, KNSA

The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record of strong recoveries, with the sector typically seeing double-digit gains after a downturn. This is something investors shouldn’t ignore. This recent turnaround can be credited to a robust increase in fundraising efforts and an uptick in IPOs, reaching levels not seen since the peak of the mid-pandemic market boom. According to the Financial Times, drug developers raised $6 billion in equity capital markets in January, the largest total since February 2021 – a period when biotech stocks hit their all-time high. Moreover, the SPDR S&P Biotech ETF (XBI) returned 28.7% over the past six months alone, clearly illustrating investors' rising confidence in the biotech rebound. Identifying biotech stocks with the potential to deliver superior returns is no easy feat. There are specific milestones that companies can achieve to signal positive momentum to investors. For example, smaller biotech companies may have received the nod from regulatory authorities such as the FDA, or new breakthroughs from clinical trials, to offer a compelling investment opportunity. With that in mind, two stocks that investors should consider looking at are Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) and Kiniksa Pharmaceuticals (NASDAQ:KNSA). Cardiol Therapeutics lead product is CardiolRx™, a small molecule therapy that appears on track to bring major disruption to the pericarditis market. CardiolRx™ received a vote of confidence as it was granted Orphan Drug Designation (ODD) by the FDA for the treatment of pericarditis back in February, illustrating the potential of the drug. Apart from providing a seven-year term of market exclusivity upon final FDA approval, the ODD also positions Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees, and certain tax credits. The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as one that affects fewer than 200,000 people in the U.S. There are approximately 160,000 cases of recurrent pericarditis in the U.S. annually, which includes 38,000 cases with a recurrence. Having secured FDA approval, Cardiol Therapeutics is an exemplary company likely to attract biotech investors seeking assurance in smaller firms. While the stock had a significant rally on the backdrop of this news and continues to show strength, we believe that there is still potential for further upside. Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) is expected to release topline data in June for its Phase 2 MAvERIC-Pilot clinical trial, which if positive, could unlock significant shareholder value. Several analysts have already indicated that they are highly optimistic that the data could be a catalyst, with one analyst noting that “CardiolRx’s potential to be a safe, new approach to RP (recurrent pericarditis) treatment is underappreciated.” CardiolRx™ stands out when compared to the only FDA-approved therapy because it is administered orally and expected to be offered as a first-line therapy for pericarditis, opening it up to an even bigger opportunity as it could be prescribed at the first occurrence. Orphan drugs have become lucrative business opportunities because these drugs command premium drug pricing, with the average price for an orphan drug at $32,000 per year per patient according to a 2021 study published in the journal Rare Diseases & Journal of Orphan Drugs. That could explain why analysts who have been tracking CRDL are so bullish on the stock. For instance, Joe Gantoss of Chimera Research Group says he won’t be surprised to see Cardiol’s price break past the 3-year high at $4.96, while analyst Vernon Bernardino of H.C. Wainwright & Co. reiterated their Buy rating and issued a $9.00 price target. That would imply that Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a potential upside of about 300% from its current share price. Kiniksa Pharmaceuticals (NASDAQ:KNSA) offers some insight into the revenue potential of an orphan drug that treats recurrent pericarditis. So far, KNSA has had a great run, gaining about 36% over the past year and trading at about $18.00 per share despite challenges in the sector. It is currently valued at $1.3 billion. Kiniksa’s portfolio of assets includes ARCALYST®, the first and only FDA-approved therapy for recurrent pericarditis. For some context, the FDA granted Breakthrough Therapy designation to ARCALYST® for recurrent pericarditis in 2019; the FDA granted Orphan Drug exclusivity to ARCALYST® in March 2021 for the treatment of recurrent pericarditis and a reduction in the risk of recurrence in adults and pediatric patients 12 years of age and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021. Sales of ARCALYST® were $38.5 million in 2021; $122.5 million in 2022; $233.2 million in 2023 further reaffirming the massive revenue potential for treating recurrent pericarditis. For the first quarter of 2024, ARCALYST® sales were $78.9 million representing 85% year-over-year growth. Furthermore, since its launch in April 2021, approximately 2,000 prescribers have written ARCALYST® prescriptions for recurrent pericarditis, illustrating the massive demand for effective recurrent pericarditis therapies. Going forward, Kiniksa anticipates that it will bring in between $370 million and $390 million in 2024, up from the earlier guidance of $360 million to $380 million. The revised outlook represents roughly 63% year-over-year growth at the midpoint. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cardiol Therapeutics to assist in the production and distribution of content related to CRDL. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

June 03, 2024 07:00 AM Eastern Daylight Time

UFC and Aires Tech Inc. Join Forces to Reach a Global Audience of 700 Million Fans

AAIRF, EDR, TKO

In a world increasingly reliant on technology, concerns about electromagnetic radiation (EMR) have led to a surge in demand for innovative solutions. American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) has been making significant strides in the tech industry with its cutting-edge approach to electromagnetic radiation (EMF) protection. The US market for EMF protection is estimated to be worth $5 billion, representing only a small portion of the even larger global opportunity. With the announcement of a multi-year global marketing partnership with UFC last week, now could be the time to take a look at AAIRF. The UFC Collaboration: AAIRF's visibility will increase significantly as a result of the partnership with UFC, the top mixed martial arts organization and a division of TKO Group Holdings (NYSE:TKO), which Endeavor Group Holdings, Inc. (NYSE: EDR) owns a majority stake in. With UFC’s reach extending to over 700 million fans in 170 countries and approximately 975 million households, this collaboration is poised to place Aires Tech in front of a massive global audience. The integration of Aires branding within UFC’s major events, including pay-per-view broadcasts and other media, will provide unparalleled reach. Grant Norris-Jones, Head of Global Partnerships at TKO, highlighted the synergy between the two brands: “Aires aligns well with our brand in several respects, including their focus on innovation and being a first mover in their industry.” Josh Bruni, CEO of Aires, emphasized the benefits of the partnership: “This collaboration not only amplifies our global reach but also connects us with UFC's dedicated audience, who value peak performance and personal well-being.” The partnership was activated at UFC 302: Makhachev vs. Poirier on June 1, 2024, marking a significant milestone in Aires' journey to become a global leader in EMF protection technology. The company hopes that this collaboration is expected to drive brand awareness and sales growth, solidifying Aires’ position as a leader in the market. Innovative Technology: The exclusive silicon-based resonator technology from Aires is intended to block dangerous electromagnetic radiation (EMR) released by consumer electronics. This innovation is embodied in their Lifetune products, which target EMR from cellphones, computers, baby monitors, Wi-Fi, and high-speed 5G networks. With over 20 years and $20 million invested in research and development, Aires has positioned itself as a pioneer in the field of EMR protection. The company's products appeal to a wide range of customers, including biohackers, athletes, individuals concerned with fertility, and those seeking better sleep. Aires operates a direct-to-consumer sales model with fulfillment centers in the USA, Canada, Australia, and the EU, and has recently established a new center in the UK to support its global expansion efforts. Financial Strength and Growth Trajectory: American Aires Inc. has demonstrated robust financial performance, with gross margins averaging around 60%. This is comparable to top technology companies like Nvidia and Apple, which boast gross margins of 75% and 45%, respectively. The company achieved positive EBITDA (adjusted) in its most recent quarter, underscoring its strong financial health. In fiscal year 2023, Aires reported a record annual order volume of $10.4 million, a 79% increase year-over-year. The company's direct-to-consumer business now ships products to over 60 countries, with significant growth observed in Australia and the EU. In Q1 2024, Aires reported a 37% year-over-year increase in sales, despite typical Q1 consumer spending weaknesses. The company's cash balance also saw a substantial improvement, increasing from $0.03 million in Q4 2023 to $2.3 million in Q1 2024, bolstered by successful financings in February and May 2024. CEO Josh Bruni stated, “Now that Q1 and our heavy lifting on the IR front are behind us, we're refocusing our efforts on deploying the capital we raised across three major fronts: forging prominent new marketing partnerships, building universal brand awareness, and expanding internationally. In other words, continuing to do what's enabled our multi-year trajectory of significant revenue growth so we can make 2024 our best year ever.” Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Clarkham Capital to assist in the production and distribution of content related to AAIRF/WIFI. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc. Mark McKelvie +1 585-301-7700 Mark@razorPitch.com Company Website http://razorpitch.com

June 03, 2024 06:00 AM Eastern Daylight Time

Tron and Ethereum Lose Momentum, Raboo Set To Surge 10x in June

Total Media

Although the crypto market is generally bullish, popular tokens like Tron and Ethereum are not performing as expected. Tron's protracted legal battles with the SEC and the delay in the official trading of the Ethereum ETF have been identified as probable causes. Meanwhile, investors remain confident in the revolutionary memetoken Raboo (RABT), which is currently gaining momentum in its presale, with over $1.5 million worth of the token sold already. Also, with a potential to surge by 10x in June, Raboo is rapidly becoming one of the best cryptos to invest in this year. Tron’s legal battles slow down momentum after price slump Tron continues to face significant legal challenges from the United States Securities and Exchange Commission (SEC). The SEC lawsuit against Tron, which has slowed down its market activity, alleges that Tron's TRX token is a security. The SEC further claimed that the sales of these tokens were not legal since they are unregistered securities offerings. Tron has firmly disputed these claims, stating that the SEC's allegations are "tenuous at best." Furthermore, Tron claims that the SEC is not a "worldwide regulator" and that its attempt to apply U.S. securities laws to "predominantly foreign conduct" goes "too far." This stance is consistent with the firm's headquarters being in Singapore. The ongoing legal challenges have impacted Tron's momentum given that Tron has been down by more than 6% for a month. Crypto analysts have identified its ongoing legal battles as the root of this decline, given that investors have become increasingly cautious about investing in Tron’s platform with the ongoing regulatory issues. Ethereum’s ETF trading delay slows price growth Ethereum's recent rally has fizzled out, indicating a loss of momentum even though backers of the project continue to affirm that it is still one of the best crypto to invest in this year. The token is expected to witness increased trading activity due to the approval of spot Ethereum exchange-traded funds (ETFs) by the United States Securities and Exchange Commission (SEC), however, the ETFs are yet to commence trading officially as investors await the respective Form S-1 approval for each fund. This development has led crypto analysts to speculate that the uncertainty that accompanies such inactive moments could spell trouble for Ethereum's price, particularly given the high futures open interest that rose to its highest level ever on May 28. The recent approval of 19b-4s forms issued by the Ethereum ETF issuers does not mean that trading in Ethereum ETFs has begun. The S-1 forms, which include detailed financial and risk information, are yet to be approved by the SEC and could take weeks. This delay in trading has contributed to the lack of market activity which has slowed down growth and has led crypto analysts to believe that Ethereum would continue to lose momentum in the meantime. Raboo tipped to 10X in June as AI meme coin surges on massive adoption Raboo, the new AI meme coin, is expected to surge 10x in June, according to analysts. This prediction is based on the token's unique social-fi model, which allows holders to earn extra tokens by competing in challenges and giveaways. Crypto enthusiasts also stand the chance to earn returns by engaging the platform. Raboo's integration of AI technology continues to drive its growth, positioning it as one of the best altcoins to buy in 2024. While massive purchase of its presale token that has now exceeded the $1.5 million mark is projected to inspire a 10x surge in June, crypto analysts have also predicted that Raboo's price will grow 233% during the presale and 100x on launch day. This rapid growth is attributed to the token's innovative features that are designed to attract memecoin enthusiasts. Raboo's surge in June is expected to be 10x after being tipped as the best altcoin to buy in 2024. Raboo is well-positioned to become one of the best altcoins in the industry as more crypto enthusiasts join the platform, increasing its strong community while its innovative features continue to captivate investors. Investors looking for a high-growth opportunity should consider Raboo, which is expected to 100x this year. Conclusion Tron and Ethereum continue to face challenges amidst ongoing lawsuits and reduced trading activity that has inspired a loss of momentum for both tokens. Meanwhile, Raboo, an innovative memecoin that has been tipped as the best crypto to buy in 2024, continues to attract more investors after record surge positioning it for massive returns in June and lucrative returns for investors upon launch. You can participate in the Raboo presale here Telegram: https://t.me/RabootokenPortal Twitter: https://twitter.com/Raboo_Official Contact Details Total Media Solutions media@Totalsolutionspr.io

June 02, 2024 02:13 PM Eastern Daylight Time

Image

All Industries

The Beachbody Company (NYSE: BODI) Reports Achieving Positive Turnaround In Revenue, EBITDA And Cash Flow In Q1 2024

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Introducing the SIGMA 28-45mm F1.8 DG DN | Art, the First Full-Frame F1.8 Zoom Lens for Mirrorless Camera Systems

BestGrowthStocks.com Issues Comprehensive Evaluation of Sirius XM Holdings Inc

NobleMarriage Launches Advanced Matrimonial App for Muslims Seeking Life Partners

BestGrowthStocks.com Issues Comprehensive Evaluation of GameStop Corporation

Sector Spotlight: Orphan Drug Developers With Significant Upside

UFC and Aires Tech Inc. Join Forces to Reach a Global Audience of 700 Million Fans

Tron and Ethereum Lose Momentum, Raboo Set To Surge 10x in June